Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
Rhea-AI Summary
Castle Biosciences (Nasdaq: CSTL) will release fourth-quarter and full-year 2025 financial results after market close on Thursday, Feb. 26, 2026. Management will host a conference call and webcast at 4:30 p.m. Eastern the same day with a brief Q&A and a replay available.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CSTL declined 7.32%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CSTL fell 10.22% while peers FLGT (-2.07%), CDNA (-7.93%), MYGN (-1.69%), PSNL (-10.84%) and NEO (-4.77%) also traded lower. Momentum scanner did not flag a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 11 | Preliminary 2025 results | Positive | +0.8% | Preliminary FY2025 revenue above guidance and strong core test growth. |
| Dec 19 | Inducement equity grants | Neutral | -0.4% | RSU inducement grants to new employees under Nasdaq Listing Rule 5635(c)(4). |
| Dec 17 | Clinical study results | Positive | +1.6% | Large UM study showing DecisionDx-UM + PRAME outperform mutation analysis. |
| Dec 12 | Meta-analysis data | Positive | +1.7% | Systematic review confirming TissueCypher improves Barrett’s Esophagus risk stratification. |
| Dec 09 | Expert endorsement | Positive | +0.4% | Expert panel paper recommending DecisionDx-Melanoma as best-practice tool. |
Recent company-specific news has generally led to modest, positively aligned price reactions, especially around strong operating updates and supportive clinical or scientific data.
Over the past few months, Castle Biosciences reported several milestones. On Jan. 11, 2026, preliminary unaudited 2025 results indicated total revenue expected to exceed $340 million, with strong growth in core test volumes and year-end cash and marketable securities of about $300 million, and the stock rose 0.81%. December 2025 brought inducement equity grants, multiple favorable clinical and outcomes publications for DecisionDx and TissueCypher, and an expert consensus paper endorsing DecisionDx-Melanoma, each associated with small positive or neutral price moves. Today’s scheduling of the formal Q4/FY25 release and call follows that preliminary update.
Market Pulse Summary
The stock moved -7.3% in the session following this news. A negative reaction despite this being an earnings date announcement would contrast with the modestly positive responses to recent operational and clinical updates, including the preliminary FY2025 results that saw a 0.81% move higher. The stock already traded 21.05% below its 52-week high before this release, and insider activity over the past months reflected net selling. Such factors could amplify downside pressure if the forthcoming results or commentary fail to meet expectations formed after the preliminary numbers.
AI-generated analysis. Not financial advice.
FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the close of market on Thursday, Feb. 26, 2026.
Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.
Conference Call and Webcast Details
A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/483643109, or via the webcast link on the Investor Relations page of the Company’s website: https://ir.castlebiosciences.com/overview/default.aspx. Please access the webcast at least 10 minutes before the conference call start time. A replay of the webcast will be available following the conclusion of the conference call.
To access the live conference call via phone, please dial 1 833 470 1428 from the United States, at least 10 minutes prior to the start of the call, using the access code 695618. International dial-in numbers are available here: https://www.netroadshow.com/events/global-numbers?confId=94133; please use the same access code above to join the call.
There will be a brief Question and Answer session following management commentary.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.
We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Instagram, Facebook and X.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
FAQ
When will Castle Biosciences (CSTL) release Q4 and full-year 2025 results?
How can investors access Castle Biosciences (CSTL) Feb. 26, 2026 conference call and webcast?
Will a replay of the Castle Biosciences (CSTL) Feb. 26, 2026 webcast be available after the call?
What topics will Castle Biosciences management cover on the Feb. 26, 2026 call?
What international dial-in options exist for Castle Biosciences (CSTL) Feb. 26, 2026 call?
